Traitement par le Ca-DTPA des contaminations internes par le plutonium et l’américium : Recommandations pour la rédaction de protocoles dans les centres CEA et AREVA

Grappin, L.; Legoff, J.-P.; Carbone, L.; Courtay, C.; Agrinier, Anne-Laure; Aninat, Mauricio; Amabile, J.-C.; Florin, Anne; André, Fiona

doi:10.1051/radiopro/2009022

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, an early treatment schedule has been proposed which corresponds to daily i.v. of Ca-DTPA (0.5 g) for 3 d, three times a week for 3 weeks and MODELLING Pu/Am/Cm DECORPORATION BY DTPA once a week for 3 months (16) . Figure 6 shows after wound contamination the effective dose reduction for type M or S 239 Pu, associated with such a schedule and the dose benefits if treatment is continued for 5 or 50 y at different time intervals.…”

Section: Simulations To Improve Dose Reduction By Dtpamentioning

confidence: 99%

MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy

Fritsch¹,

Grémy²,

Hurtgen

et al. 2010

Radiation Protection Dosimetry

Self Cite

View full text Add to dashboard Cite

models have been developed to describe dissolution of Pu/Am/Cm after internal contamination by inhalation or wound, chelation of actinides by diethylene triamine penta acetic acid (DTPA) in different retention compartments and excretion of actinide-DTPA complexes. After coupling these models with those currently used for dose calculation, the modelling approach was assessed by fitting human data available in IDEAS database. Good fits were obtained for most studied cases, but further experimental studies are needed to validate some modelling hypotheses as well as the range of parameter values. From these first results, radioprotection tools are being developed: MAnagement of DOse Reduction after DTPA therapy.

show abstract

Section: Simulations To Improve Dose Reduction By Dtpamentioning

confidence: 99%

MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy

Fritsch¹,

Grémy²,

Hurtgen

et al. 2010

Radiation Protection Dosimetry

Self Cite

View full text Add to dashboard Cite

show abstract

“…plutonium (Pu) or americium (Am), can cause severe health damage due to the continuous alpha irradiation of organs and tissues such as the lungs, liver and skeleton, where they can be retained for decades (ICRP 2019 ). Treatment with the chelating agent DTPA (diethylenetriaminepentaacetic acid) as a salt of calcium (Ca) or zinc (Zn) is the commonly used therapy to remove Pu/Am from the body (Ménétrier et al 2005 ; Grappin and Bérard 2008 ; Grappin et al 2006 , 2007a , b , 2009 ). Indeed, the injection or inhalation of Ca/Zn–DTPA enhances the excretion of the incorporated actinide by forming stable An–DTPA chelates, thus minimizing the amount of An retained in the body and the resulting committed effective dose.…”

Section: Introductionmentioning

confidence: 99%

Modelling DTPA therapy following Am contamination in rats

Kastl,

Grémy,

Lamart

et al. 2023

Radiat Environ Biophys

View full text Add to dashboard Cite

A major challenge in modelling the decorporation of actinides (An), such as americium (Am), with DTPA (diethylenetriaminepentaacetic acid) is the fact that standard biokinetic models become inadequate for assessing radionuclide intake and estimating the resulting dose, as DTPA perturbs the regular biokinetics of the radionuclide. At present, most attempts existing in the literature are empirical and developed mainly for the interpretation of one or a limited number of specific incorporation cases. Recently, several approaches have been presented with the aim of developing a generic model, one of which reported the unperturbed biokinetics of plutonium (Pu), the chelation process and the behaviour of the chelated compound An–DTPA with a single model structure. The aim of the approach described in this present work is the development of a generic model that is able to describe the biokinetics of Am, DTPA and the chelate Am–DTPA simultaneously. Since accidental intakes in humans present many unknowns and large uncertainties, data from controlled studies in animals were used. In these studies, different amounts of DTPA were administered at different times after contamination with known quantities of Am. To account for the enhancement of faecal excretion and reduction in liver retention, DTPA is assumed to chelate Am not only in extracellular fluids, but also in hepatocytes. A good agreement was found between the predictions of the proposed model and the experimental results for urinary and faecal excretion and accumulation and retention in the liver. However, the decorporation from the skeletal compartment could not be reproduced satisfactorily under these simple assumptions.

show abstract

Rischio radiologico: Gestione medica delle vittime di incidenti radiologici

Laroche

Gagna²,

Castagnet

et al. 2014

EMC - Urgenze

View full text Add to dashboard Cite

Traitement par le Ca-DTPA des contaminations internes par le plutonium et l’américium : Recommandations pour la rédaction de protocoles dans les centres CEA et AREVA

Abstract: Article published by EDP Sciences and available at http://www.radioprotection.org or http://dx

Cited by 5 publications

References 3 publications

MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy

MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy

Modelling DTPA therapy following Am contamination in rats

Rischio radiologico: Gestione medica delle vittime di incidenti radiologici

Contact Info

Product

Resources

About